CTA
ALDR

Carillon Tower Advisers’s Alder Biopharmaceuticals ALDR Stock Holding History

Carillon Tower Advisers’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,281,760
Closed -$14.7K – 484
2017
Q4 		$14.7K Buy
+1,281,760
New +$14.3M 0.16% 194

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Carillon Tower Advisers's ALDR Position: Q1 2018 in Review

Carillon Tower Advisers sold out of Alder Biopharmaceuticals (ALDR) in Q1 2018, closing a stake of 1,281,760 shares — an estimated $14.7K sold.

Carillon Tower Advisers first reported a position in ALDR in Q4 2017 and held it in 1 quarter. The position peaked at $14.7K in Q4 2017. 135 funds tracked by Wall St. Rank hold ALDR as of Q1 2018.

  • Carillon Tower Advisers reported no remaining Alder Biopharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Carillon Tower Advisers sold 1,281,760 Alder Biopharmaceuticals shares in Q1 2018, an estimated $14.7K.
  • Carillon Tower Advisers first reported a position in Alder Biopharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Carillon Tower Advisers's Alder Biopharmaceuticals position peaked at $14.7K in Q4 2017.
  • 135 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q1 2018.

Based on Carillon Tower Advisers's 13F filing for Q1 2018, filed 14 May 2018.